Changchun GeneScience Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1948-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://english.ciac.cas.cn/
Assessment of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of GenSci120 in Healthy Adult Participants in China.
Not Applicable
Not yet recruiting
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-06-27
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT07040930
- Locations
- 🇨🇳
Huashan Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
A Clinical Study of GenSci134 in Healthy Male Adults
Phase 1
Not yet recruiting
- Conditions
- Healthy Volunteers
- Interventions
- Drug: GenSci134Drug: GenSci134 PlaceboDrug: Recombinant Human Growth Hormone Injection (Norditropin®)
- First Posted Date
- 2025-06-12
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 64
- Registration Number
- NCT07016802
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
Real-World Clinical Study for Malignant Tumor-Induced Cachexia
Recruiting
- Conditions
- Clinical Characteristics and Treatment Outcomes of Malignant Tumor CachexiaMulticenter Observational Study
- First Posted Date
- 2025-06-06
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 6000
- Registration Number
- NCT07008248
- Locations
- 🇨🇳
Xuzhou Central Hospital, Xuzhou Clinical School of Xuzhou Medical University, Xuzhou, Jiangsu, China
A Study on Bioequivalence of Cabergoline Tablets in Human Body
Phase 1
Not yet recruiting
- Conditions
- Hyperprolactinemia
- Interventions
- Drug: Cabergoline tablets test formulationDrug: Cabergoline tablets reference formulation
- First Posted Date
- 2025-06-06
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 72
- Registration Number
- NCT07008417
The Study Will Evaluate if Leuprolide Mesylate is Safe and Effective in the Treatment of Subjects With Advanced Prostate Carcinoma, When Administered as Two Injections Six Months Apart.
Phase 3
Completed
- Conditions
- Advanced Prostate Cancer
- Interventions
- Drug: Leuprolide Injectable Emulsion (CAMCEVI®)
- First Posted Date
- 2025-05-22
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 137
- Registration Number
- NCT06984159
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
A Bioavailability Study of GS1-144 Tablets in Healthy Postmenopausal Women
Phase 1
Not yet recruiting
- Conditions
- Healthy Postmenopausal Women
- Interventions
- Drug: GS1-144 Tablet with new preparation (T)Drug: GS1-144 Tablet with present preparation (R)
- First Posted Date
- 2025-05-21
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT06983925
- Locations
- 🇨🇳
Chengdu Xinhua Hospital, Chengdu, Sichuan, China
A Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 in Patients With Moderate to Severe Endometriosis-Associated Pain
Phase 2
Not yet recruiting
- Conditions
- Endometriosis-related Pain
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-05-08
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT06963177
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase
Phase 3
Not yet recruiting
- Conditions
- Extensive-stage Small Cell Lung Cancer (ES-SCLC)The Pre-cachexia or Cachexia Patients Who Have Not Received Systemic Treatment and Are Not Eligible for Curative Therapy
- Interventions
- Drug: Nano-crystalline Megestrol Acetate Oral SuspensionDrug: standard treatment
- First Posted Date
- 2025-05-07
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 94
- Registration Number
- NCT06961201
- Locations
- 🇨🇳
West China School of Medicine/West China Hospital of Sichuan University, Chengdu, Sichuan, China
Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis
Phase 3
Not yet recruiting
- Conditions
- Metastatic (Stage IV) Non-squamous Non-small Cell Lung Cancer (Nsq-NSCLC) With Driver Gene NegativityUntreated With Systemic Therapy
- Interventions
- Drug: Nano-crystalline Megestrol Acetate Oral SuspensionOther: Standard Therapy
- First Posted Date
- 2025-05-07
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 174
- Registration Number
- NCT06961188
- Locations
- 🇨🇳
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Real-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in TKI-Treated Advanced Digestive Tumors
Recruiting
- Conditions
- CachexiaDigestive System CancerGastric CancerColorectal CancerHepatocellular Carcinoma
- Interventions
- Drug: Nano-crystalline Megestrol Acetate Oral SuspensionDrug: TKI-Based Therapy
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06940102
- Locations
- 🇨🇳
General Hospital of Northern Theater Command, Shenyang, Liaoning, China
🇨🇳Liaoning Cancer Hospital, Shenyang, Liaoning, China